Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2021
Extended dosing of monoclonal antibodies in multiple sclerosisZoé LE van Kempen, Alyssa A Toorop, Finn Sellebjerg, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 15, 2020
COVID-19 in multiple sclerosis: The Dutch experienceFloor C Loonstra, Elske Hoitsma, Zoé LE van Kempen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 26, 2019
Infusion-related events during natalizumab: No need for post-infusion monitoringFloor C Loonstra, Johannis A van Rossum, Zoé LE van Kempen, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 19, 2026
Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactionsLisa G Schoof, Laura Hogenboom, Zoé LE van Kempen, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2022
Fingerprick blood samples to measure serum natalizumab concentrationsAlyssa A Toorop, Maurice Steenhuis, Floris C Loeff, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 24, 2017
Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrationsZoé LE van Kempen, Cyra E Leurs, Anke Vennegoor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 10, 2017
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosingZoé LE van Kempen, Cyra E Leurs, Birgit I Witte, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 22, 2017
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patientsCyra E Leurs, Zoé LE van Kempen, Iris Dekker, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2021
Natalizumab concentrations during pregnancy in three patients with multiple sclerosisAlyssa A Toorop, Theo Rispens, Eva Mm Strijbis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 18, 2024
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosisAlyssa A Toorop, Samantha Noteboom, Martijn D Steenwijk, et al.
Pageof 2